- Home
- SNDX vs GIII Comparison
SNDX vs GIII Comparison
Compare SNDX & GIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- GIII
- Stock Information
- Founded
- SNDX 2005
- GIII 1956
- Country
- SNDX United States
- GIII United States
- Employees
- SNDX N/A
- GIII N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- GIII Apparel
- Sector
- SNDX Health Care
- GIII Consumer Discretionary
- Exchange
- SNDX Nasdaq
- GIII Nasdaq
- Market Cap
- SNDX 1.6B
- GIII 1.5B
- IPO Year
- SNDX 2016
- GIII 1989
- Fundamental
- Price
- SNDX $15.83
- GIII $30.33
- Analyst Decision
- SNDX Strong Buy
- GIII Hold
- Analyst Count
- SNDX 11
- GIII 7
- Target Price
- SNDX $36.00
- GIII $30.43
- AVG Volume (30 Days)
- SNDX 1.7M
- GIII 319.5K
- Earning Date
- SNDX 11-05-2024
- GIII 12-03-2024
- Dividend Yield
- SNDX N/A
- GIII N/A
- EPS Growth
- SNDX N/A
- GIII N/A
- EPS
- SNDX N/A
- GIII 4.01
- Revenue
- SNDX $16,000,000.00
- GIII $3,086,394,000.00
- Revenue This Year
- SNDX N/A
- GIII $5.35
- Revenue Next Year
- SNDX $219.92
- GIII $1.69
- P/E Ratio
- SNDX N/A
- GIII $7.57
- Revenue Growth
- SNDX N/A
- GIII N/A
- 52 Week Low
- SNDX $14.81
- GIII $20.66
- 52 Week High
- SNDX $25.34
- GIII $35.68
- Technical
- Relative Strength Index (RSI)
- SNDX 32.96
- GIII 46.27
- Support Level
- SNDX $16.03
- GIII $30.77
- Resistance Level
- SNDX $17.87
- GIII $31.73
- Average True Range (ATR)
- SNDX 0.93
- GIII 0.95
- MACD
- SNDX -0.45
- GIII -0.07
- Stochastic Oscillator
- SNDX 1.26
- GIII 25.00
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
About GIII G-III Apparel Group LTD.
G-III Apparel Group Ltd is a textile company. It makes a wide range of apparel, footwear, and accessories that it sells under its own brands, licensed brands, and private-label brands. G-III has a substantial portfolio for licensed and proprietary brands, anchored by five global power brands: DKNY, Donna Karan, Calvin Klein, Tommy Hilfiger, and Karl Lagerfeld. The company has two reportable operations: Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, as well as sales of products under its own brands and private label brands. The retail operations segment consists primarily of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives most of its revenues from Wholesale operations.